(Q33909851)

30 July 2017

1 reference

title

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). (English)

1 reference

amyotrophic lateral sclerosis

30 July 2017

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (English)

0 references

main subject

0 references

author name string

R G Miller

1

1 reference

30 July 2017

J D Mitchell

2

1 reference

30 July 2017

D H Moore

3

1 reference

30 July 2017

M Lyon

3

0 references

D H Moore

4

0 references

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

2002

0 references

2001

0 references

published in

1 reference

30 July 2017

CD001447

1 reference

30 July 2017

2

1 reference

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.

30 July 2017

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447

Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447

10.1002/14651858.CD001447

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference